$PMCB If PharmaCyte proves that its live-cell encapsulation technology works in a pancreatic cancer clinical trial, the company should immediately get lots of attention for its diabetes treatment. A cell encapsulation type delivery system is the "holy grail" for a diabetes treatment, and PharmaCyte would immediately be on the map and likely contacted by many companies wanting to help them advance their treatment for diabetes or buy it outright. With regard to the cancer treatment, if the results are as good as the company expects them to be, then there is a very good likelihood that a buyer will;
1.) buy the treatment outright, which could immediately give the company $3-5 billion and raise the share price with that value in mind
2.) buy the company outright - buying the cancer and diabetes and cannabis treatments
3.) buy the company for the cancer only - leaving the company to spin off another company with the diabetes/cannabis treatments if they chose to continue to develop those
4.) PharmaCyte could license the cancer treatment in Asia, Europe, the United States, South America etc. to different companies and get paid a licensing fee forever, which would give them plenty of money to develop their other treatments, or
5.) PharmaCyte could sell the cancer, and then look for a buyer for the diabetes/cannabis treatments. In any scenario, the price of PharmaCyte or the payoff to shareholders would be exponentially higher than the prices we are seeing today.
News 
Market Data 
Discover 
